Physician profile
Craig Silverman
NPI 1770698169
$8,732.28
in general payments reported to CMS, 2019-2025
51 companies · $1,507 in 2025
The $1,507 reported for 2025 was more than what 88% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,548 · 2020: $1,307 · 2021: $646 · 2022: $462 · 2023: $1,109 · 2024: $1,153 · 2025: $1,507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,769.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,569.81 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $709.61 | 2019-2025 | Tagrisso, Enhertu, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $693.94 | 2019-2025 | Opdivo |
| Eisai INC. | $556.88 | 2019-2024 | |
| Novocure INC. | $508.56 | 2019-2025 | Optune Gio, Optune |
| Amgen INC. | $410.07 | 2019-2021 | |
| Incyte Corporation | $366.85 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Novartis Pharmaceuticals Corporation | $329.87 | 2019-2025 | |
| Astellas Pharma US INC | $297.13 | 2019-2025 | Vyloy, Xospata |
| Seagen INC. | $289.14 | 2019-2023 | Tukysa, Adcetris |
| Celgene Corporation | $257.87 | 2019-2025 | Opdivo |
| Gt Medical Technologies, INC | $215.66 | 2025 | Gammatile |
| Daiichi Sankyo INC. | $197.19 | 2019-2025 | Enhertu, Datroway |
| Bayer Healthcare Pharmaceuticals INC. | $189.04 | 2019-2025 | |
| Pfizer INC. | $170.32 | 2019-2025 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.